Nchi: Afrika Kusini
Lugha: Kiingereza
Chanzo: South African Health Products Regulatory Authority (SAHPRA)
Lundbeck
CLOPIXOL® TABLETS 2 mg CLOPIXOL® TABLETS 10 mg SCHEDULING STATUS: S5 PROPRIETARY NAME (and dosage form): CLOPIXOL ® TABLETS 2 mg CLOPIXOL ® TABLETS 10 mg COMPOSITION: Each tablet contains zuclopenthixol dihydrochloride equivalent to 2 mg or 10 mg zuclopenthixol. PHARMACOLOGICAL CLASSIFICATION: A 2.6.5 Thioxanthenes PHARMACOLOGICAL ACTION: CLOPIXOL is a thioxanthene derivative with pronounced antipsychotic and specific dampening effect. The antipsychotic effect of neuroleptics is normally related to their dopamine receptor blocking effect, which seems to release a chain reaction as other transmitter systems are influenced as well. The bioavailability after oral administration is 25-40%. Maximum serum concentration is reached after about 4 hours. Highly significant correlations exist between the dose and the area under the serum concentration curves. CLOPIXOL is distributed in the organism in the same way as seen for other neuroleptics with the highest concentrations of drug and metabolites in liver, lung, intestines and kidneys and lower concentrations in heart, spleen and brain. Autoradiographic studies in mice show that small amounts of radioactive labelled drug and/or metabolites cross the placenta barrier and that some radioactivity is excreted with milk. The metabolism proceeds along three main routes - sulphoxidation, side chain N - dealkylation and glucuronic acid conjugation. The metabolites are not psychopharmacologically active. The biological half-life in humans is about 20 hours. The elimination proceeds mainly with faecal excretion being 8-11 times urinary excretion in rats. INDICATIONS: Symptoms of restlessness, agitation, hostility, aggression, psychomotor excitement and other behavioural disturbances in acute and chronic schizophrenia, manic phase of bipolar affective dis Soma hati kamili